On October 12-13, the BioCon Asia 2023-Advanced Cell & Gene Therapy (ACGT) Conference was held in Singapore. The conference focused on the latest developments in the Cell and Gene Therapy (CGT) industry, including innovative discoveries, recent case studies, clinical data, and business prospects in areas such as CAR-T/TCR-T, UCAR-T products, and gene therapy technologies based on AAV vectors. Over 300 distinguished industry leaders and immunotherapy scientists from around the world attended the conference.
Dr. Dudu Tong, the R&D Director of Leman Biotech, participated in the conference and delivered a presentation titled "Metabolically armed CAR-T cells for treatment of solid tumors." In the presentation, he introduced the detailed mechanism of Leman Biotech's metabolic reprogramming technology (Meta 10), developed by the founding team, to overcome T cell exhaustion. He also discussed the preclinical and Investigator-Initiated Trial (IIT) clinical trial results of the metabolically enhanced CAR-T cells developed based on this technology.
Preclinical studies showed that Meta 10 significantly improves the immune response rate and cure rate for solid tumors, demonstrating great potential for curing solid tumors. The metabolically enhanced CAR-T cell therapy targeting CD19, developed on this basis, showed promising preliminary results in the IIT clinical trial. Ten patients have undergone treatment, and the first nine patients achieved clinical cures and were discharged with extremely low doses (1%~5% of conventional therapeutic doses). Currently, Leman Biotech is actively advancing the development of metabolically enhanced solid tumor CAR-T and collaborating with multiple partners to promote the application and clinical translation of Meta 10 in various forms of immunotherapy.
